Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's AUTL AUTO1 (obecabtagene autoleucel, obe-cel).
The Company's CAR T cell therapy is being investigated in the ongoing FELIX Phase 1b/2 study in relapsed/refractory adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older.
Price Action: AUTL shares are up 5.11% at $6.38 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

Momentum21.59

GrowthNot Available

QualityNot Available

Value7.71

Short

Medium

Long